Oncology

A new study has unveiled a groundbreaking cancer treatment approach using engineered extracellular vesicles to target both tumor cells and immunosuppressive stromal cells in the tumor microenvironment (TME).

A recent observational study has shown that AI can significantly enhance breast cancer detection rates in mammography screening without increasing unnecessary recalls.

Post-transplant care has demonstrated that collaboration between hematopoietic cell transplantation (HCT) specialists and local oncologists can safely enhance patient outcomes while reducing caregiver burdens in a recently published research article.

A Phase III clinical trial, ECHELON-3, has demonstrated survival benefits for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) using a combination therapy of brentuximab vedotin (BV), lenalidomide (Len), and rituximab (R).

Significant advancements in tailoring salvage therapy for pediatric patients with relapsed or refractory classic Hodgkin lymphoma (cHL) have been revealed in a recent clinical trial.

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.